RxDoctor Payments Data

Paulino Alvarez

Advanced Heart Failure and Transplant Cardiology · Iowa City, IANPI 1073874210

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,074 of the $1,772 with a category attached, or 60.6%. 7 manufacturers reported payments, led by Medical Device Business Services, Inc. at 38.5% of the total. Reporting peaked in 2019 at $635 and has fallen 69.3% since, to $195 in 2025.

$1,772in general payments, 2019–2025

Across 19 payments — averaging $93.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$681
  • Abbott$644
  • Cvrx, Inc.$169
  • Edwards Lifesciences$133
  • Heartflow, Inc.$116
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15
  • plus $15 from 1 others

What the payments were for

  • Travel & lodging$171%
  • Food & beverage$1,07461%
  • Education$68138%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$76,852
Medicare patients
304
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis181$4,058,321
EntrestoSacubitril/Valsartan358$473,830
JardianceEmpagliflozin390$455,971
VyndaqelTafamidis Meglumine12$260,493
EliquisApixaban217$245,027
FarxigaDapagliflozin Propanediol55$57,751
NexletolBempedoic Acid22$15,071
XareltoRivaroxaban13$11,211
Metoprolol Succinate452$6,809
Torsemide197$3,544
Potassium Chloride80$2,999
Atorvastatin Calcium160$1,981
Isosorbide Dinitrate38$1,979
Carvedilol153$1,489
Spironolactone237$1,471

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →